? Clinical Protocol and Data Management The Central Protocol and Data Monitoring Office (CPDMO) within the St. Jude Comprehensive Cancer Center (SJCCC) provides centralized administrative, regulatory, and educational services for clinical trials-related activities. It is the coordinating center for protocol standardization, regulatory and compliance guidance, administrative submissions, protocol registration data, and monitoring. The CPDMO is integral to the Clinical Trials Administration (CTA), which provides comprehensive infrastructure for conducting SJCCC clinical trials. Together, the CTA and CPDMO perform the following functions to provide outstanding clinical trials support to SJCCC members: (1) Facilitate the development of high-quality clinical trials, within a standardized framework, to meet institutional and federal requirements. (2) Maintain a centralized submission process for institutional review and approval. (3) Set standards by fostering consistent conduct and compliance through the monitoring of all clinical trials. (4) Ensure appropriate participant enrollment via a centralized clinical trials registration system. (5) Provide infrastructure and coordinate trials at affiliate and collaborating institutions. (6) Adhere to the Data Safety Monitoring Plan, which was revised and approved by the NCI in August 2017. The CPDMO also provides administrative support to the Clinical Trials Scientific Review Committee to ensure the thorough scientific review of all trials in the SJCCC. Studies are monitored commensurate with the degree of risk to participants and the size and complexity of the study. The SJCCC's Data Safety Monitoring Board is composed of external experts who independently oversee institutional Phase III trials and high-risk trials; an Internal Monitoring Committee assesses findings from individual audit reports and safety trends and recommends educational and corrective actions. Trial monitoring and safety reporting is the responsibility of all members of the clinical trial process. Particular attention is paid to monitoring investigator-initiated trials (IITs), especially those with no external monitoring program. The CPDMO presently includes 42 staff members. Over the current funding period, the number of new pediatric patients with cancer increased 11%, from 459 in FY 2013 to 516 in FY2017: 60% enrolled into interventional therapeutic trials, and 90% of those were in institutional IITs. Similarly, the CPDMO assisted with 5,470 enrollments into interventional (therapeutic and nontherapeutic) trials, a 23% increase in accrual into this category, compared to the previous funding period. In addition, we assisted with 30,071 enrollments into non-interventional clinical trials. During the current funding period, the CPDMO managed more than 406 prospective trials, of which 52% are institutional IITs. During FY2017, the CPDMO's portfolio, subdivided by sponsor, included 61% IIT/peer reviewed, 32% national alliance/consortia, and 7% industrial. The SJCCC supported 30 investigational new drug applications and new device exemptions for 36 IITs. Presently, the CPDMO supports 116 active multisite IITs. The CPDMO is committed to serving all SJCCC members by supporting the efficient and effective conduct of high-quality translational and clinical pediatric cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA021765-40
Application #
9632021
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-03-01
Budget End
2020-02-29
Support Year
40
Fiscal Year
2019
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Varedi, Mitra; Lu, Lu; Howell, Carrie R et al. (2018) Peripheral Neuropathy, Sensory Processing, and Balance in Survivors of Acute Lymphoblastic Leukemia. J Clin Oncol 36:2315-2322
Zhang, Yingchi; Gao, Yufeng; Zhang, Hui et al. (2018) PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood 131:2256-2261
Vuotto, Stefanie C; Ojha, Rohit P; Li, Chenghong et al. (2018) The role of body image dissatisfaction in the association between treatment-related scarring or disfigurement and psychological distress in adult survivors of childhood cancer. Psychooncology 27:216-222
Allen, Jennifer; Willard, Victoria W; Klosky, James L et al. (2018) Posttraumatic stress-related psychological functioning in adult survivors of childhood cancer. J Cancer Surviv 12:216-223
Santiago, Teresa; Hayes, Caleb; Polanco, Ana Concepción et al. (2018) Improving Immunohistochemistry Capability for Pediatric Cancer Care in the Central American and Caribbean Region: A Report From the AHOPCA Pathology Working Group. J Glob Oncol :1-9
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Wang, Zhaoming; Liu, Qi; Wilson, Carmen L et al. (2018) Polygenic Determinants for Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: The St Jude Lifetime Cohort Study (SJLIFE). Clin Cancer Res 24:6230-6235
Paulk, Nicole K; Pekrun, Katja; Zhu, Erhua et al. (2018) Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol Ther 26:289-303
Bjornard, Kari L; Gilchrist, Laura S; Inaba, Hiroto et al. (2018) Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health 2:744-754
Gibson, Todd M; Li, Chenghong; Armstrong, Gregory T et al. (2018) Perceptions of future health and cancer risk in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 124:3436-3444

Showing the most recent 10 out of 6764 publications